1. Home
  2. IFRX vs RGS Comparison

IFRX vs RGS Comparison

Compare IFRX & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.64

Market Cap

66.0M

Sector

Health Care

ML Signal

HOLD

Logo Regis Corporation

RGS

Regis Corporation

N/A

Current Price

$28.00

Market Cap

66.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
IFRX
RGS
Founded
2007
1922
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
66.0M
66.4M
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
IFRX
RGS
Price
$2.64
$28.00
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$6.25
N/A
AVG Volume (30 Days)
3.1M
7.1K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.24
EPS
N/A
0.89
Revenue
N/A
$210,134,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$32.02
Revenue Growth
N/A
3.52
52 Week Low
$0.71
$18.23
52 Week High
$2.95
$31.50

Technical Indicators

Market Signals
Indicator
IFRX
RGS
Relative Strength Index (RSI) 69.16 56.08
Support Level $0.97 $25.95
Resistance Level $2.95 $28.51
Average True Range (ATR) 0.29 0.97
MACD -0.02 -0.05
Stochastic Oscillator 68.37 71.55

Price Performance

Historical Comparison
IFRX
RGS

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About RGS Regis Corporation

Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.

Share on Social Networks: